I assume it is another Phase 2a study based on -
"The purpose of the study is to look at the safety and tolerability of trofinetide in children and adolescents with Rett syndrome. The study will also investigate the effectiveness of trofinetide during treatment."
From rettstudy.com
- Forums
- ASX - By Stock
- NEU
- Rett Syndrome Study - new site
Rett Syndrome Study - new site, page-12
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B |
Open | High | Low | Value | Volume |
$14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $16.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.57 | 1717 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 16.520 |
2 | 400 | 16.480 |
1 | 300 | 16.470 |
2 | 1367 | 16.440 |
2 | 5242 | 16.400 |
Price($) | Vol. | No. |
---|---|---|
16.570 | 1717 | 1 |
16.590 | 1367 | 2 |
16.600 | 4715 | 3 |
16.620 | 2306 | 2 |
16.650 | 2000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online